Is It Too Late for Novavax to Profit From a Covid-19 Vaccine?

Syndicated by: https://www.nasdaq.com/articles/is-it-too-late-for-novavax-to-profit-from-a-covid-19-vaccine-2020-10-22 “Novavax‘s vaccine candidate will not likely be the first to market, but will stand in contrast to the mRNA vaccines by Moderna and Pfeizer. As I understand it, mRNA biotechnology allows for faster scaled production. However, it is brand-new technology which has never been used commercially in humans. The way mRNA vaccines work is scary and sounds very close to genetic engineering or editing. In contrast, Novavax uses a tried-and-true method to produce immunity. News media and social media are almost certain to hype up reports of side effects during the first round of vaccination. Vaccine hesitancy is growing, and in 2018 almost half of US citizens refused a flu vaccine. Waiting a few more months for Novavax‘s vaccine candidate would appeal to vaccine hesitant individuals who are not fully anti-vax.” Source: https://www.statista.com/topics/5166/vaccine-hesitancy-in-the-us/